drugset / Trial / NCT02535221
Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study proposes to prove that the efficacy of adjuvant endocrine therapy for the premenopausal HR positive breast cancer patients is non-inferiority to adjuvant chemotherapy assessed by ultrasound response rate.
Timeline
- Start
- 2015-07-29
- Primary completion
- 2026-06-30
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anastrozole | Other / unclassified | 1 mg | Oral |
| Comparator | CTX | Unknown | 600 mg/m2 | — |
| Comparator | Epirubicin | Small molecule | 80 mg/m2 | — |
| Comparator | Epirubicin | Small molecule | 100 mg/m2 | — |
| Subject | Goserelin | Other / unclassified | 3.6 mg | Subcutaneous |
| Subject | Tamoxifen | Small molecule | 10 mg | Oral |
| Comparator | fluorouracil | Small molecule | 200 mg/m2 | — |
| Comparator | fluorouracil | Small molecule | 600 mg/m2 | — |